BRTX, a biotechnology company in its industry, exhibits strong compliance in debt (0%) and non-permissible income (0%) ratios but fails significantly in liquidity (63.58%) and interest income (642.35%) metrics, leading to non-compliance across major Shariah standards. The core business in regenerative medicine is permissible, with no non-compliant activities identified. However, financial anomalies due to low revenue amplify riba exposure. Index exclusion confirms overall non-compliance, though purification is required for any incidental income. Investors should monitor for improvements in revenue generation to reduce ratio distortions.